Is compounded semaglutide safe?
Compounded semaglutide is not an FDA-approved product and has never been reviewed for safety, efficacy or quality. That is a statement about its legal status rather than a finding that it is dangerous, and the difference between those two things is the whole answer.
No clinician has reviewed this page. Label and trial statements are quoted from the FDA label or the trial cited beside them. General guidance is marked as such, and every price carries the date it was verified. That is sourcing, not medical review. What we do and do not check · Who checked the price
Last updated 2026-09-22 — the prices and figures quoted below. Read and dated by Alex Seot.
What does compounded mean, and what has nobody checked?
A compounding pharmacy makes a drug to order rather than buying the manufacturer's finished product. It is legal under an exemption in federal law, and it exists for real reasons: a patient who cannot tolerate a dye in the approved version, a dose the manufacturer does not make, a genuine shortage.
What the exemption does not include is FDA review. The approved product went through trials the agency assessed and is made in facilities it inspects to that standard. A compounded copy skips both. Nothing about that makes a given vial bad; it means nobody outside the pharmacy has checked.
What the warning letters actually say
halfrx stores 156 FDA warning letters touching compounded semaglutide and tirzepatide, each linked to its original on fda.gov. They are worth reading rather than counting: the recurring findings are sterility failures, potency that does not match the label, and salt forms — semaglutide sodium or acetate — which the FDA states are different active ingredients from the one in the approved drugs and were never the subject of any trial.
A warning letter is the agency's statement of a violation it has found at a named facility. It is not a court ruling and it is not a statement about every compounded product. It is, however, the only systematic public record of what goes wrong, which is why it belongs in this answer rather than a general reassurance.
The price gap, which is why the question exists
The cheapest compounded semaglutide with a verified all-in price here is $129 a month (Strut Health); the cheapest FDA-approved semaglutide for weight is $299 (Medvi) — $170 a month apart. Nobody takes an unreviewed product for fun; they take it because of that number.
Which makes the honest framing this: the question is not whether compounded semaglutide is safe in the abstract, but whether the gap is worth an unreviewed supply chain and a legal status that can end. Manufacturer lawsuits over the compounding exemption are live, and a pharmacy that is enjoined stops shipping to the people relying on it.
What to ask before starting one
Which molecule and which salt form. Semaglutide base is the approved substance; sodium and acetate salts are not, and a pharmacy that will not say which it uses has answered the question.
Whether the pharmacy is 503A or 503B. A 503B outsourcing facility registers with the FDA and is inspected to a higher standard than a 503A, which compounds per prescription.
What happens if supply stops. An injunction against a pharmacy is not hypothetical in this category, and a plan that assumes continuity is a plan with a gap in it.
None of the above is medical advice, and whether this route suits a particular person is a conversation with a prescriber.
Questions
- Is compounded semaglutide the same drug as Wegovy?
- The same molecule, if the pharmacy is using semaglutide base. Not the same product: Wegovy is a specific formulation, made under inspected conditions, tested in trials the FDA assessed. A compounded version is a copy of the active ingredient without any of that behind it.
- Is it legal?
- Compounding is legal under a federal exemption. Whether these specific products fall inside it is being litigated by the manufacturers, and the answer has changed before and can change again.
- How would I know if a batch was bad?
- Usually you would not, which is the point. Potency problems are invisible without testing — the failure mode is a dose that does less or more than the label says. Report anything unexpected to your prescriber and to the FDA's MedWatch program.
- Do doctors recommend compounded semaglutide?
- The medical societies that have said anything say no. The Obesity Medicine Association, The Obesity Society and the Obesity Action Coalition told patients in January 2024: “we do not recommend the use of these alternatives.” The American Diabetes Association’s statement of December 2024 recommends against non-FDA-approved compounded GLP-1 and GIP/GLP-1 products. Both were written while semaglutide was in shortage, when compounding copies of it was allowed at scale. FDA declared that shortage resolved on 21 February 2025, and its page on unapproved GLP-1s, current as of 1 September 2026, says compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug. By 31 May 2026 it had received 990 reports of adverse events associated with compounded semaglutide.
What this rests on
- FDA: concerns with unapproved GLP-1 drugs used for weight lossThe salt forms. The agency states that semaglutide sodium and semaglutide acetate “are different active ingredients than are used in the approved drugs”, and that it has no information on whether they behave the same way.
- FDA: compounding and the FDA, questions and answersThat compounded drugs are not FDA approved, are not reviewed for safety, effectiveness or quality before they are marketed, and exist under an exemption for needs an approved drug cannot meet.
- FDA: registered outsourcing facilitiesThe 503A and 503B distinction, and which facilities are registered and inspected as outsourcing facilities.
- FDA prescribing information for WEGOVY (semaglutide)What the approved product's formulation, trials and warnings actually are, which is the thing a compounded copy is being compared against.
- FDA MedWatch adverse event reportingWhere an unexpected reaction is reported.
- Obesity Medicine Association, The Obesity Society and Obesity Action Coalition: statement to patients on compounded GLP-1 alternativesThe joint recommendation of 8 January 2024 against compounded alternatives.
- American Diabetes Association: statement on compounded incretin productsThe recommendation of 2 December 2024 against non-FDA-approved compounded GLP-1 and GIP/GLP-1 products.
- FDA: policies for compounders as national GLP-1 supply stabilizesThe dates the shortages were declared resolved: tirzepatide on 19 December 2024, semaglutide on 21 February 2025.
Every figure above is read from the page of the drug or seller it names, which records where it came from and the date it was verified. Every clinical statement is quoted from one of the labels listed above, never interpreted. Information only, not medical advice.